Summary & Overview
CPT 84163: Pregnancy-Associated Plasma Protein A (PAPP-A) Quantitation
CPT code 84163 designates a quantitative assay for pregnancy-associated plasma protein A (PAPP-A), a first-trimester biochemical marker used in prenatal screening for chromosomal aneuploidies such as Down syndrome (trisomy 21) and for assessing certain pregnancy complications. Nationally, this laboratory test is an important component of early prenatal risk assessment and is commonly ordered alongside other first-trimester screening elements.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for CPT code 84163, typical sites of service, and common billing considerations. The publication summarizes payer coverage patterns, standard modifiers observed in practice, and how CPT code 84163 fits into prenatal screening workflows.
This resource provides benchmarks and policy-relevant context for administrators, laboratory managers, and clinicians involved in prenatal screening programs. It highlights what to expect when coding and billing for a PAPP-A quantitation and outlines where to look for payer-specific coverage rules and reimbursement policies. Data not available in the input where specific payer policies, taxonomies, or ICD-10 pairings would normally be listed.
Billing Code Overview
CPT code 84163 describes a laboratory assay that quantifies pregnancy-associated plasma protein A (PAPP-A). This test is typically performed in the first trimester of pregnancy to assess fetal risk factors, most commonly as part of screening for Down syndrome (trisomy 21) and to evaluate risk for certain pregnancy complications.
-
Service type: First-trimester prenatal biochemical screening / quantitative immunoassay
-
Typical site of service: Clinical laboratory or hospital laboratory performing prenatal screening
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 32-year-old pregnant person at 11 weeks gestation presents to an outpatient maternal-fetal medicine clinic for routine first-trimester aneuploidy screening. The clinician orders a first-trimester screening panel that includes measurement of pregnancy-associated plasma protein A (PAPP-A) performed on a venous blood specimen. The laboratory analyst processes the specimen, runs the quantitative immunoassay for PAPP-A (84163), documents the numeric result in the laboratory information system, and transmits the result to the ordering clinician. The clinician integrates the PAPP-A value with ultrasound nuchal translucency measurement and maternal age to calculate risk for fetal trisomy 21 and other chromosomal abnormalities. Results may also inform assessment of risk for placental-related complications such as preeclampsia or intrauterine growth restriction. Typical sites of service include outpatient obstetrics clinics, hospital outpatient laboratories, and independent clinical laboratories. The specimen collection is performed by phlebotomy staff; testing is performed by clinical laboratory personnel with appropriate chemistry/immunoassay instrumentation. Billing uses laboratory CPT 84163 for the analytic component of the PAPP-A test.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified modifier |